These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 33011111)

  • 1. The Origin of Ovarian Cancer Species and Precancerous Landscape.
    Shih IM; Wang Y; Wang TL
    Am J Pathol; 2021 Jan; 191(1):26-39. PubMed ID: 33011111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic landscape and evolutionary trajectories of ovarian cancer precursor lesions.
    Wu RC; Wang P; Lin SF; Zhang M; Song Q; Chu T; Wang BG; Kurman RJ; Vang R; Kinzler K; Tomasetti C; Jiao Y; Shih IM; Wang TL
    J Pathol; 2019 May; 248(1):41-50. PubMed ID: 30560554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence for lineage continuity between early serous proliferations (ESPs) in the Fallopian tube and disseminated high-grade serous carcinomas.
    Soong TR; Howitt BE; Miron A; Horowitz NS; Campbell F; Feltmate CM; Muto MG; Berkowitz RS; Nucci MR; Xian W; Crum CP
    J Pathol; 2018 Nov; 246(3):344-351. PubMed ID: 30043522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma.
    Norris EJ; Zhang Q; Jones WD; DeStephanis D; Sutker AP; Livasy CA; Ganapathi RN; Tait DL; Ganapathi MK
    J Pathol; 2019 Jul; 248(3):352-362. PubMed ID: 30883751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Morphologic features of fallopian tubal epithelium in pelvic high-grade serous carcinoma].
    Zhao RJ; Wang YY; Li Z; Wu KY; Kong LF; Zheng WX
    Zhonghua Bing Li Xue Za Zhi; 2017 Aug; 46(8):542-547. PubMed ID: 28810294
    [No Abstract]   [Full Text] [Related]  

  • 6. The genomic trajectory of ovarian high-grade serous carcinoma can be observed in STIC lesions.
    Cheng Z; Ennis DP; Lu B; Mirza HB; Sokota C; Kaur B; Singh N; Le Saux O; Russo G; Giannone G; Tookman LA; Krell J; Barnes C; McDermott J; McNeish IA
    J Pathol; 2024 Sep; 264(1):42-54. PubMed ID: 38956451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in serous tubal intraepithelial carcinoma: correlation with high grade serous carcinoma and ovarian carcinogenesis.
    Li HX; Lu ZH; Shen K; Cheng WJ; Malpica A; Zhang J; Wei JJ; Zhang ZH; Liu J
    Int J Clin Exp Pathol; 2014; 7(3):848-57. PubMed ID: 24696706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 9.
    Saini U; Suarez AA; Naidu S; Wallbillich JJ; Bixel K; Wanner RA; Bice J; Kladney RD; Lester J; Karlan BY; Goodfellow PJ; Cohn DE; Selvendiran K
    Cancer Res; 2018 Apr; 78(7):1739-1750. PubMed ID: 29339537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fallopian Tube Lesions in Women at High Risk for Ovarian Cancer: A Multicenter Study.
    Visvanathan K; Shaw P; May BJ; Bahadirli-Talbott A; Kaushiva A; Risch H; Narod S; Wang TL; Parkash V; Vang R; Levine DA; Soslow R; Kurman R; Shih IM
    Cancer Prev Res (Phila); 2018 Nov; 11(11):697-706. PubMed ID: 30232083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary.
    Leonhardt K; Einenkel J; Sohr S; Engeland K; Horn LC
    Int J Gynecol Pathol; 2011 Sep; 30(5):417-24. PubMed ID: 21804388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-grade Serous Carcinoma Occurring in a Serous Cystadenoma on the Background of a Serous Tubal Intraepithelial Carcinoma (STIC)-like Lesion: A Case Report With Literature Review.
    Novikov FV; Anufriev AG; Efremov GD
    Int J Gynecol Pathol; 2024 Nov; 43(6):626-630. PubMed ID: 38661558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methylomic Landscapes of Ovarian Cancer Precursor Lesions.
    Pisanic TR; Wang Y; Sun H; Considine M; Li L; Wang TH; Wang TL; Shih IM
    Clin Cancer Res; 2020 Dec; 26(23):6310-6320. PubMed ID: 32817081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Probing the tumorigenic potential of genetic interactions reconstituted in murine fallopian tube organoids.
    Maru Y; Tanaka N; Tatsumi Y; Nakamura Y; Yao R; Noda T; Itami M; Hippo Y
    J Pathol; 2021 Oct; 255(2):177-189. PubMed ID: 34184756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Morphologic changes of fallopian tubal epithelium in ovarian serous tumors].
    Wen J; Shi JL; Shen DH; Chen YX; Song QJ
    Zhonghua Bing Li Xue Za Zhi; 2012 Jul; 41(7):433-7. PubMed ID: 22932451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell Origins of High-Grade Serous Ovarian Cancer.
    Kim J; Park EY; Kim O; Schilder JM; Coffey DM; Cho CH; Bast RC
    Cancers (Basel); 2018 Nov; 10(11):. PubMed ID: 30424539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytomorphologic and molecular analyses of fallopian tube fimbrial brushings for diagnosis of serous tubal intraepithelial carcinoma.
    Chui MH; Vang R; Wang TL; Shih IM; VandenBussche CJ
    Cancer Cytopathol; 2019 Mar; 127(3):192-201. PubMed ID: 30861338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fallopian tube precursors of ovarian low- and high-grade serous neoplasms.
    Vang R; Shih IeM; Kurman RJ
    Histopathology; 2013 Jan; 62(1):44-58. PubMed ID: 23240669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical Expression Status of p53, CD44v9, and Ki-67 in a Series of Fallopian Tube Lesions of High-grade Serous Carcinoma.
    Sugimoto S; Uchiyama T; Kawahara N; Ohbayashi C; Kobayashi H
    Int J Gynecol Pathol; 2021 Sep; 40(5):419-426. PubMed ID: 34397764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defining the molecular evolution of extrauterine high grade serous carcinoma.
    Beirne JP; McArt DG; Roddy A; McDermott C; Ferris J; Buckley NE; Coulter P; McCabe N; Eddie SL; Dunne PD; O'Reilly P; Gilmore A; Feeney L; Ewing DL; Drapkin RI; Salto-Tellez M; Kennedy RD; Harley IJG; McCluggage WG; Mullan PB
    Gynecol Oncol; 2019 Nov; 155(2):305-317. PubMed ID: 31493898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.